Comprehensive Safety Analysis Reveals Distinct Adverse Event Profiles Across Anti-HER2 Drug Classes in Breast Cancer Treatment
核心洞察
A large-scale pharmacovigilance study analyzing 47,799 adverse event reports from the FAERS database identified distinct safety profiles for three classes of anti-HER2 (搜索) drugs used in breast cancer treatment.
Trastuzumab deruxtecan (T-DXd) showed the highest mortality rate at 23.86% among all seven drugs studied, with significant respiratory system adverse events, while trastuzumab demonstrated the strongest cardiac toxicity signals.
Tyrosine kinase inhibitors, particularly neratinib, exhibited the strongest gastrointestinal adverse event signals, with diarrhea being the most frequently reported side effect in this drug class.
A comprehensive pharmacovigilance analysis of anti-HER2 (搜索) drugs has revealed significant differences in adverse event profiles across three major drug classes used to treat HER2-positive breast cancer, providing crucial insights for clinical decision-making and patient safety monitoring.
The study, which analyzed 47,799 adverse event reports from the FDA Adverse Event Reporting System (FAERS) database spanning from 2004 to 2024, examined seven anti-HER2 (搜索) drugs across three therapeutic classes: monoclonal antibodies (pertuzumab, trastuzumab), antibody-drug conjugates (T-DXd, T-DM1), and tyrosine kinase inhibitors (lapatinib, neratinib, tucatinib).
Mortality Patterns Reveal ADC Drug Risks
Among the most striking findings, trastuzumab deruxtecan (T-DXd) demonstrated the highest mortality rate at 23.86%, significantly exceeding all other anti-HER2 (搜索) therapies studied. This finding aligns with the drug's uniquely high drug-to-antibody ratio of approximately 8, compared to T-DM1's ratio of 3.5. The elevated mortality risk associated with T-DXd was nearly twice that of T-DM1 (14.81%), highlighting important safety considerations for this newer ADC therapy.
Conversely, pertuzumab showed the lowest mortality rate at 9.38%, despite trastuzumab having a higher absolute number of adverse event reports due to its longer market presence since 1998.
Cardiac Toxicity Dominates Monoclonal Antibody Profile
The analysis revealed that monoclonal antibodies, particularly trastuzumab, carry the strongest signals for cardiac disorders. Trastuzumab showed a reporting odds ratio (ROR) of 3.51 for cardiac disorders, with cardiotoxicity representing the highest risk (ROR: 12.71). Left ventricular dysfunction emerged as the second most significant cardiac adverse event (ROR: 6.57).
Pertuzumab also demonstrated significant cardiac toxicity signals, though with lower intensity than trastuzumab. The drug showed particular risks for cardiac dysfunction (ROR: 8.89) and blood and lymphatic system disorders.
Distinct Organ System Targeting by Drug Class
Each drug class exhibited characteristic adverse event patterns affecting different organ systems. T-DM1 showed the strongest signal for hepatobiliary disorders (ROR: 3.09), consistent with known dose-dependent hepatotoxicity risks. Meanwhile, T-DXd demonstrated significant respiratory system adverse events (ROR: 2.33), with respiratory, thoracic, and mediastinal disorders representing the most significant system organ class for this drug.
All three tyrosine kinase inhibitors showed pronounced gastrointestinal adverse event signals, with neratinib exhibiting the strongest signal (ROR: 4.70), followed by lapatinib (ROR: 2.50). Diarrhea emerged as the most frequently reported and highest-risk adverse event for TKI drugs, with lapatinib accounting for 2,240 reported cases.
Hospitalization Risk Factors Identified
Multivariate logistic regression analysis identified key risk factors for hospitalization across drug classes. For monoclonal antibodies, infections and infestations, surgical and medical procedures, and respiratory disorders represented the highest hospitalization risks. ADC drugs showed particular risks related to infections and infestations, with T-DXd showing endocrine disorders as the most significant risk factor for hospitalization (OR: 22.7).
Among TKI drugs, lapatinib demonstrated the most complex risk profile with 11 system organ classes increasing hospitalization risk, while tucatinib showed relatively fewer risk factors, suggesting a potentially more favorable safety profile within this drug class.
Geographic and Demographic Patterns
The analysis revealed that adverse event reporting was concentrated in economically developed regions, with Europe, North America, and Asia showing the highest case numbers. Patients aged 45-64 years represented the largest proportion of adverse event reports across all drug classes, reflecting the typical breast cancer patient demographic.
Notably, 85.64% of reported adverse events occurred in female patients, consistent with breast cancer epidemiology, though this also reflects the predominant use of these drugs in female breast cancer patients.
Clinical Implications for Patient Monitoring
The findings provide specific guidance for clinical monitoring strategies. Healthcare providers should implement enhanced cardiac monitoring for patients receiving trastuzumab and pertuzumab, with particular attention to cardiotoxicity and left ventricular function. Patients receiving T-DM1 require careful hepatic function monitoring, while those on T-DXd need respiratory system surveillance.
For TKI therapy, proactive gastrointestinal management becomes crucial, with healthcare professionals advised to recommend fluid and electrolyte supplementation as needed, particularly for patients receiving neratinib or lapatinib.
The study's comprehensive analysis of real-world adverse event data provides healthcare providers with evidence-based insights for optimizing patient safety across the spectrum of anti-HER2 (搜索) therapies, enabling more informed treatment decisions and targeted monitoring strategies in HER2-positive breast cancer management.